Extracorporeal myocardial shockwave therapy; a precious blast for refractory angina patients

Slavich, Massimo; Pizzetti, Giuseppe; Vella, Anna Maria; Carlucci, Claudia; Margonato, Davide; Spoladore, Roberto; Fragasso, Gabriele; Margonato, Alberto

doi:10.1016/j.carrev.2017.09.018

Cited by 11 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Low-intensity Extracorporeal Shockwave Therapy (Leswt)supporting

confidence: 63%

“…Past studies have demonstrated that LESWT can repair endothelial damage and improve tissue blood supply in rat cavernous tissue [ 64 ]. Consistent with these findings, LEWT pretreatment of penile tissue prior to radical prostatectomy significantly reduced inflammatory markers in cavernous tissue and attenuated a series of injury complexes resulting from cavernous nerve pathway injury, while LEWST inhibited apoptosis and promoted cell proliferation and microvascular regeneration within the tissue [ 65 ].…”

Section: Stem Cell Therapy (Sct)mentioning

confidence: 99%

See 1 more Smart Citation

Cavernous Nerve Injury Resulted Erectile Dysfunction and Regeneration

Jiang

Xingqin

et al. 2021

Journal of Immunology Research

View full text Add to dashboard Cite

Erectile dysfunction (ED) is an important cause of reduced quality of life for men and their partners. Recent studies have found that cavernous nerve injury (CNI) during prostate cancer surgery and other pelvic surgery results in medically induced CNIED in more than 80% of patients. The efficacy of first- and second-line treatment options for ED is poor. A great deal of research has been devoted to exploring new methods of neuroprotection and nerve regeneration to save erectile function in patients with CNIED, especially in patients with cavernous nerve injury after prostate cancer surgery. In addition, such as neuromodulatory proteins, proimmune ligands, gene therapy, stem cell therapy, and the current cutting-edge low-energy shock wave therapy have shown advantages in basic research and limited clinical studies. In the context of today’s modern medicine, these new therapeutic techniques are expected to be new tools in the treatment of cavernous nerve injury erectile dysfunction. This article presents the main causes, mechanisms, and treatment of cavernous nerve injury erectile dysfunction and combines them with new treatment strategies.

show abstract

Section: Low-intensity Extracorporeal Shockwave Therapy (Leswt)supporting

confidence: 63%

Section: Stem Cell Therapy (Sct)mentioning

confidence: 99%

Cavernous Nerve Injury Resulted Erectile Dysfunction and Regeneration

Jiang

Xingqin

et al. 2021

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…The number of studies included involving LVEF were 12 [ 4 , 9 , 11 , 12 , 16 - 18 , 20 , 21 , 24 , 27 , 29 ] , with a total of 566 patients. The included study types were nine single-arm studies, two cohort studies, and one RCT.…”

Section: Resultsmentioning

confidence: 99%

Cardiac Shock Wave Therapy for Coronary Heart Disease: an Updated Meta-analysis

Huang¹,

Xie²,

Hou³

et al. 2020

Braz J Cardiovasc Surg

View full text Add to dashboard Cite

Introduction The aim of this article is to study the efficacy and safety of cardiac shock wave therapy (CSWT) in the treatment of coronary heart disease (CAD). Methods A comprehensive search of electronic databases and a manual search of conference papers and abstracts were performed until September 30, 2018. The studies using RevMan 5.3 and STATA 14.0 softwares were reviewed, and meta-analyses were performed on 13 indicators, such as a six-min walking distance test (6MWT), New York Heart Association (NYHA) functional class, Seattle Angina Questionnaire (SAQ) score, angina class (Canadian Cardiology Society [CCS]), etc. Results A total of 26 articles were included. The total patient population was 855, of which 781 patients were treated with CSWT. Meta-analyses indicated that 6MWT (mean difference [MD] 75.64, 95% confidence interval [CI] 49.03, 102.25, P <0.00001) and NYHA (MD -0.70, 95% CI -0.92) in the CSWT group were comparable to those in the conventional revascularization group (MD -0.70, 95% CI -0.92, -0.49, P <0.00001). SAQ (MD 10.75, 95% CI 6.66, 14.83, P <0.00001), CCS (MD -0.99, 95% CI -1.13, -0.84, P <0.00001), nitrate dosage (MD -1.84, 95% CI -2.77, -1.12, P <0.00001), LVEF (MD 3.77, 95% CI 2.17, 5.37, P <0.00001), and SSS (MD -4.29, 95% CI -5.61, -2.96, P <0.00001), SRS (MD -2.90, 95% CI -4.85, -0.95, P =0.004), and the exercise test (standard mean difference 0.57, 95% CI 0.12, 1.02, P =0.01) all showed significant differences. Conclusion CSWT may offer beneficial effects to patients with CAD, but more large-scale clinical studies are needed to further verify its therapeutic effect.

show abstract

“…In the past decades, several studies across different medical disciplines have indicated the therapeutic efficacy of ESWT to various degrees against diverse medial conditions, including spasticity after upper motor neuron injury [26], tendinopathies, musculoskeletal conditions and soft tissue disorders [27][28][29][30][31][32], refractory angina pectoris [33], erectile dysfunction [34], and sexual conditions other than erectile dysfunction [35,36]. While several studies have also suggested that the use of ESWT exerts a beneficial effect in patients with CP/CPPS [8,[15][16][17][18][19][20][21][22][23][24], as with erectile dysfunction [37], the application of ESWT in the management of CP/CPPS is not without its controversies [23,25].…”

Section: Discussionmentioning

confidence: 99%

Extracorporeal Shockwave Therapy (ESWT) Alleviates Pain, Enhances Erectile Function and Improves Quality of Life in Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Bamodu

Wang

et al. 2021

JCM

View full text Add to dashboard Cite

Purpose: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), affecting over 90% of patients with symptomatic prostatitis, remains a therapeutic challenge and adversely affects patients’ quality of life (QoL). This study probed for likely beneficial effects of ESWT, evaluating its extent and durability. Patients and methods: Standardized indices, namely the pain, urinary, and QoL domains and total score of NIH-CPSI, IIEF-5, EHS, IPSS, and AUA QoL_US were employed in this study of patients with CP/CPPS who had been refractory to other prior treatments (n = 215; age range: 32–82 years; median age: 57.5 ± 12.4 years; modal age: 41 years). Results: For CP symptoms, the mean pre-ESWT NIH-CPSI total score of 27.1 ± 6.8 decreased by 31.3–53.6% over 12 months after ESWT. The mean pre-ESWT NIH-CPSI pain (12.5 ± 3.3), urinary (4.98 ± 2.7), and QoL (9.62 ± 2.1) domain scores improved by 2.3-fold, 2.2-fold, and 2.0-fold, respectively, by month 12 post-ESWT. Compared with the baseline IPSS of 13.9 ± 8.41, we recorded 27.1–50.9% amelioration of urinary symptoms during the 12 months post-ESWT. For erectile function, compared to pre-ESWT values, the IIEF-5 also improved by ~1.3-fold by month 12 after ESWT. This was corroborated by EHS of 3.11 ± 0.99, 3.37 ± 0.65, 3.42 ± 0.58, 3.75 ± 0.45, and 3.32 ± 0.85 at baseline, 1, 2, 6, and 12 months post-ESWT. Compared to the mean pre-ESWT QoL score (4.29 ± 1.54), the mean QoL values were 3.26 ± 1.93, 3.45 ± 2.34, 3.25 ± 1.69, and 2.6 ± 1.56 for months 1, 2, 6, and 12 after ESWT, respectively. Conclusions: This study shows ESWT, an outpatient and easy-to-perform, minimally invasive procedure, effectively alleviates pain, improves erectile function, and ameliorates quality of life in patients with refractory CP/CPPS.

show abstract

Extracorporeal myocardial shockwave therapy; a precious blast for refractory angina patients

Cited by 11 publications

References 21 publications

Cavernous Nerve Injury Resulted Erectile Dysfunction and Regeneration

Cavernous Nerve Injury Resulted Erectile Dysfunction and Regeneration

Cardiac Shock Wave Therapy for Coronary Heart Disease: an Updated Meta-analysis

Extracorporeal Shockwave Therapy (ESWT) Alleviates Pain, Enhances Erectile Function and Improves Quality of Life in Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Contact Info

Product

Resources

About